Glycopyrrolate inhalation - Circassia Pharmaceuticals

Drug Profile

Glycopyrrolate inhalation - Circassia Pharmaceuticals

Alternative Names: Glycopyrronium bromide - Circassia; PSX 1002-GB; PSX-1002; PSX1002-GB pMDI

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prosonix
  • Developer Circassia
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Jun 2015 Phase-II development is ongoing in United Kingdom
  • 23 Jan 2014 Top-line efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease released by Prosonix
  • 30 Sep 2013 Prosonix completes a phase II trial in Chronic obstructive pulmonary disease in United Kingdom (NCT01703624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top